Company Filing History:
Years Active: 2002-2011
Title: The Innovations of Urs Christoph Hofmeier
Introduction
Urs Christoph Hofmeier is a notable inventor based in St. Pantaleon, Switzerland. With a remarkable portfolio featuring five patents, his contributions significantly impact the field of pharmaceuticals and drug formulations. His expertise lies in the development of novel crystal modifications, which are instrumental in improving dosage forms of specific compounds.
Latest Patents
Hofmeier's latest patents include an innovative crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide. This invention encompasses dosage forms and formulations that utilize crystal modification A, characterized by distinct interplanar spacings determined through X-ray powder pattern analysis. The formulations are designed for both oral and parenteral administration and can be prepared in solid or liquid forms, with a dosage range of 20 mg to less than 500 mg. Notably, solid dosage forms may include tablets or capsules that incorporate a pharmaceutically acceptable carrier and film-coat. Additionally, his work on crystal modifications B and C of the same compound enhances the pharmaceutical preparations available, showcasing his innovative approach to drug formulation technologies.
Career Highlights
Throughout his career, Urs Christoph Hofmeier has collaborated with influential companies in the pharmaceutical sector, including Novartis AG and Solvias AG. His tenure at these companies has bolstered his expertise in developing innovative drug formulations and contributed to significant advancements in the industry.
Collaborations
Hofmeier has also worked alongside esteemed colleagues such as Martin Szelagiewicz and Robert Portmann. These collaborations have further enriched his research endeavors and expanded the impact of his work in the pharmaceutical field.
Conclusion
Urs Christoph Hofmeier's inventive spirit and dedication to advancing pharmaceutical science through his patented innovations illustrate his valuable contributions to the industry. With his ongoing research and commitment to developing new dosage forms, Hofmeier continues to pave the way for future advancements in drug formulations and therapies.